Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply - PubMed (original) (raw)

Comment

. 2019 May 9;380(19):1881-1882.

doi: 10.1056/NEJMc1902837.

Affiliations

• PMID: 31067395
• DOI: 10.1056/NEJMc1902837

Comment

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply

Stephen D Wiviott et al. N Engl J Med. 2019.

No abstract available

PubMed Disclaimer

Comment on

• Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
  Baglioni P. Baglioni P. N Engl J Med. 2019 May 9;380(19):1880-1881. doi: 10.1056/NEJMc1902837. N Engl J Med. 2019. PMID: 31067393 No abstract available.
• Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
  Akinci B. Akinci B. N Engl J Med. 2019 May 9;380(19):1881. doi: 10.1056/NEJMc1902837. N Engl J Med. 2019. PMID: 31067394 No abstract available.

Similar articles

• Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
  Baglioni P. Baglioni P. N Engl J Med. 2019 May 9;380(19):1880-1881. doi: 10.1056/NEJMc1902837. N Engl J Med. 2019. PMID: 31067393 No abstract available.
• Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
  Akinci B. Akinci B. N Engl J Med. 2019 May 9;380(19):1881. doi: 10.1056/NEJMc1902837. N Engl J Med. 2019. PMID: 31067394 No abstract available.
• Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
  Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Zelniker TA, et al. Circulation. 2020 Apr 14;141(15):1227-1234. doi: 10.1161/CIRCULATIONAHA.119.044183. Epub 2020 Jan 27. Circulation. 2020. PMID: 31983236
• Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
  Davis PN, Ndefo UA, Oliver A. Davis PN, et al. J Pharm Pract. 2016 Apr;29(2):165-71. doi: 10.1177/0897190014566308. Epub 2015 Jan 21. J Pharm Pract. 2016. PMID: 25609661 Review.
• Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes.
  Al-Bazz DY, Wilding JP. Al-Bazz DY, et al. Future Cardiol. 2020 Mar;16(2):77-88. doi: 10.2217/fca-2019-0065. Epub 2020 Jan 9. Future Cardiol. 2020. PMID: 31914812 Review.

Cited by

• Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand.
  Kongmalai T, Prawjaeng J, Hadnorntun P, Leelahavarong P, Chaikledkaew U, Thakkinstian A, Srinonprasert V. Kongmalai T, et al. Pharmacoecon Open. 2024 Sep 22. doi: 10.1007/s41669-024-00526-2. Online ahead of print. Pharmacoecon Open. 2024. PMID: 39306816
• The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus.
  Liu S, Ke J, Feng X, Wang Z, Wang X, Yang L, Zhao D. Liu S, et al. J Diabetes Res. 2024 Mar 28;2024:2431441. doi: 10.1155/2024/2431441. eCollection 2024. J Diabetes Res. 2024. PMID: 38577301 Free PMC article.
• Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects.
  Chen X, Tripathy D, Chilton R, Hansis-Diarte A, Salehi M, Solis-Herrera C, Cersosimo E, DeFronzo RA. Chen X, et al. Diabetes. 2024 Jun 1;73(6):896-902. doi: 10.2337/db23-0457. Diabetes. 2024. PMID: 38512770 Clinical Trial.
• The double burden: type 1 diabetes and heart failure-a comprehensive review.
  Julián MT, Pérez-Montes de Oca A, Julve J, Alonso N. Julián MT, et al. Cardiovasc Diabetol. 2024 Feb 12;23(1):65. doi: 10.1186/s12933-024-02136-y. Cardiovasc Diabetol. 2024. PMID: 38347569 Free PMC article. Review.
• Prescription patterns of antidiabetic and cardiovascular preventive medications in community-dwelling older adults with type 2 diabetes mellitus: a cross-sectional study.
  Chahine B, Souheil FA, Hanna V. Chahine B, et al. J Geriatr Cardiol. 2023 Dec 28;20(12):867-876. doi: 10.26599/1671-5411.2023.12.002. J Geriatr Cardiol. 2023. PMID: 38161340 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information